Skip to Content


MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society


Non-Motor Symptoms in Parkinson's Disease Study Group

Main Content

Join now »

Have questions? Contact the group’s MDS Staff Liaison, Allie Oakley, at


  1. To collect new and novel patient and carer reported information on Non-Motor Symptoms (NMS) of Parkinson’s disease from around the world
  2. To develop a MDS version of a new PD non motor symptoms scale
  3. To ensure that comprehensive and unified NMS assessments in clinical trials and scientific studies are increasingly used to increase the “real life” value of clinical trials and clinical studies
  4. To develop new and novel NMS instruments for use in clinics:
    • PD pain scale (currently in development and validation)
    • Vision scale
    • Sexual dysfunction scale
    • Urinary symptoms scale
  5. To set up and start international cross cultural studies, to improve existing tools for NMS (e.g. NMSS and NMSQ)
  6. To develop animal models addressing non-motor phenotypes of PD
  7. To refine, validate and establish non-motor subtypes of PD and related biomarkers


Ongoing Projects

The NM-PD study group will aim to complete and publish 3 key studies adopted from the work of the international Parkinson's Disease Non-Motor Group (PDNMG). These are:

  • The EuroInf study: Multicentre, European study comparing key motor, non-motor and quality of life effects of advanced conventional therapies apomorphine infusion, intrajejunal levodopa infusion and subthalamic nucleus deep brain stimulation in PD. Data presented at the MDS congress in Sydney, June 2013.
  • The DAICE-ET study: Multicentre European study of real life comparison of immediate release, long-acting and transdermal dopamine agonists and tolerability in elderly patients with a focus on impulse control disorders. Data presented at the MDS Congress in Sydney, June 2013.
  • EURO-DAWS study: Multi-centre European prospective survey of range, nature and frequency of dopamine agonist withdrawal syndrome in Parkinson’s disease.
  • The definition, characterization and frequency of non-motor sub-types of PD and possible biomarkers exploration.
  • The development, and clinical validation of the MDS PD non-motor symptoms scale.

Current work packages include:

  • WP 1: Non-motor subtypes and biomarkers
  • WP 2: Development of the MDS- NMS scale
  • WP 3: Animal models
  • WP 4: DBS and non-motor effects in PD
  • WP 5: Studies addressing fatigue and sleepiness in PD


K. Ray Chaudhuri

Cristian Falup-Pecurariu

Steering Committe:
K. Ray Chaudhuri
Cristian Falup-Pecurariu
Per Odin
Anette Schrag
Daniel Weintraub

Getting Involved

In addition to the MDS staff liaison, the Study Group's administrative managers are Alexandra Rizos (, Daniel Van Wamelen (, and Valentina Leta (


Themed Subgroups

Open AllClose All
  Pain and sensory symptoms

Arturo Abundes-Corona
Katarina Rukavina
Kirsty Bannister
Veronica Bruno
Veit Mylius

Michele Tinazzi
Miguel Coelho

  Sleep dysfunction

Laura Irincu
Siddharth Kharkar
Annette Hand

Cristian Falup-Pecurariu
Nicola Pavese
Ronald Postuma

  Advanced therapies

Anna Sauerbier
Haidar Dafsari
Sotirios Grigoriou

Haidar Dafsari
Lars Timmerman
Tove Henriksen
Per Odin
Fabrizio Stocchi
Eero Pekkonen
Alexander Storch

  Depression, anxiety, and psychosis

Chloe Farrell
Yi-Min Wan
Eleonora Fiorenzato
Ruth Schneider

Daniel Weintraub
Anette Schrag
Richard Brown
Paolo Barone
Melissa Nirenberg
Angelo Antonini

  Professional occupation and the impact of non-motor symptoms

Jonathan Timpka
Miriam Parry
Pavlos Zinzalias

Per Odin
Camille Carol
Richard Walker

  Complementary therapies

Indu Subramanian
Aleksandra Podlewska
Juliet Staunton
James Morley

Indu Subramanian
Michele Tagliati
Milica Kramberger
Mayela Rodriguez-Violante

Open AllClose All
  Pharmacology and basic neuroscience

Kanako Kurihara
Nobutaka Takahashi
Mahmoud Iravani

Peter Jenner
Kelly Lyons
Mario Masellis
Hideki Mochizuki

  Artificial intelligence and wearables

Jirada Sringean
Dhaval Trivedi
Daniel van Wamelen
Giovanni Gentile

Roongroj Bhidayasiri
Monica Kurtis Urra
Michele Hu
Raymond Rosales
Camille Carroll
Angelo Antonini

  Biomarkers for non-motor symptoms

Shyamal Mehta
Daniele Urso
David Coughlin
Jon Toledo
Stefanie Jost

David J Brooks
Ronald Postuma
Irene Litvan
Charles Adler
Michele Hu
Beomseok Jeon

  Autonomic and gastrointestinal dysfunction

Hafize Cotur
Valentina Leta
Katherine Longardner
Lisa Klingelhoefer
Marta Campagnolo

Fabrizio Stocchi
Per Borghammer
Yoshio Tsuboi
Jalesh Panicker

  Cognition and apathy

Rimona Weil
Lucia Batzu
Claudia Ocampo
Priya Jagota
Ece Bayram
Roberta Biundo

Daniel Weintraub
Anette Schrag
Simon Lewis
Paolo Barone
Tanya Simuni
Angelo Antonini

  Statistical cross-cutting subgroup

Carmen Rodriguez-Blazquez
João Forjaz

Pablo Martinez-Martin
Daniel Weintraub
Anette Schrag


Resource Type

Please wait while we gather your results.

Published Papers

— K. Ray Chaudhuri

“Non-motor symptoms have been the defining cry from people with Parkinson's. Pioneering work from the MDS Non-Motor Symptoms in Parkinson's Disease Study Group has led to global adoption of clinical measurement of these symptoms in real life, using novel scales and questionnaires, in addition to helping the industry start novel, cutting-edge clinical trials to address treatment of non-motor symptoms.” 


We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice